Quantamental Technologies LLC Trims Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Quantamental Technologies LLC trimmed its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 17.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,957 shares of the biopharmaceutical company’s stock after selling 1,492 shares during the quarter. Quantamental Technologies LLC’s holdings in Vanda Pharmaceuticals were worth $98,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of VNDA. Acadian Asset Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 40.7% during the 1st quarter. Acadian Asset Management LLC now owns 626,287 shares of the biopharmaceutical company’s stock worth $11,523,000 after buying an additional 181,237 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Vanda Pharmaceuticals by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 596,626 shares of the biopharmaceutical company’s stock valued at $15,588,000 after purchasing an additional 6,666 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Vanda Pharmaceuticals by 104.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 530,705 shares of the biopharmaceutical company’s stock valued at $13,867,000 after purchasing an additional 270,795 shares during the last quarter. Panagora Asset Management Inc. grew its holdings in shares of Vanda Pharmaceuticals by 12.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 470,122 shares of the biopharmaceutical company’s stock worth $6,624,000 after purchasing an additional 52,392 shares during the period. Finally, Rothschild & Co. Asset Management US Inc. grew its holdings in shares of Vanda Pharmaceuticals by 10.7% during the 2nd quarter. Rothschild & Co. Asset Management US Inc. now owns 467,212 shares of the biopharmaceutical company’s stock worth $6,583,000 after purchasing an additional 45,071 shares during the period.

In related news, SVP Timothy Williams sold 2,575 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $14.69, for a total transaction of $37,826.75. Following the sale, the senior vice president now directly owns 57,425 shares in the company, valued at $843,573.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Richard W. Dugan sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.85, for a total transaction of $222,750.00. Following the sale, the director now owns 50,770 shares in the company, valued at $753,934.50. The disclosure for this sale can be found here. 8.20% of the stock is currently owned by corporate insiders.



NASDAQ:VNDA traded up $0.16 on Wednesday, reaching $14.35. 16,942 shares of the company’s stock were exchanged, compared to its average volume of 593,369. The firm has a market capitalization of $752.17 million, a price-to-earnings ratio of 29.73 and a beta of 0.39. Vanda Pharmaceuticals Inc. has a 52-week low of $11.83 and a 52-week high of $33.44. The business has a fifty day moving average of $14.25 and a 200-day moving average of $15.83.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.24. Vanda Pharmaceuticals had a net margin of 13.61% and a return on equity of 10.23%. The business had revenue of $59.06 million during the quarter, compared to analyst estimates of $54.19 million. During the same quarter last year, the firm posted $0.15 earnings per share. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, research analysts anticipate that Vanda Pharmaceuticals Inc. will post 0.32 EPS for the current year.

A number of analysts recently issued reports on VNDA shares. ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Friday, August 2nd. Citigroup upgraded shares of Vanda Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Thursday, August 1st. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $17.00 price target on shares of Vanda Pharmaceuticals in a research note on Wednesday, July 31st. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $26.57.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Monthly Dividend Stocks Can Provide Solid Income

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.